NRAS tumor mutations are associated with reduced odds of dermatologic adverse events in patients with metastatic melanoma receiving immune checkpoint inhibitors

NRAS tumor mutations are associated with reduced odds of dermatologic adverse events in patients with metastatic melanoma receiving immune checkpoint inhibitors

Saved in:
Bibliographic Details
Main Authors: Michael S. Chang, MD, Jordan T. Said, MD, Elliot H. Akama-Garren, PhD, Nicole Trepanowski, MD, Ai-Tram N. Bui, MD, Anita Giobbie-Hurder, MS, Nicole R. LeBoeuf, MD, MPH, Rebecca I. Hartman, MD, MPH
Format: Article
Language:English
Published: Elsevier 2025-02-01
Series:JAAD International
Subjects:
anti-PD-1
anti-PDL-1
atezolizumab
avelumab
cemiplimab
dAE
Online Access:http://www.sciencedirect.com/science/article/pii/S2666328724001822
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items